Adaptive Biotech COO sells shares, exercises options
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related share sales in late March.
Rhea-AI Filing Summary
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related share sales in late March. She exercised stock options for 44,166 shares of common stock at an exercise price of $7.27 per share, then sold 57,180 shares of common stock in open-market transactions at prices in the $12–$13 range. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the trades, she directly holds 455,878 shares of Adaptive Biotechnologies common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
57,180 shs ($751K)
Approx. gross sale proceeds
$751K
Approx. exercise cost
$321K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $13.45 | $256K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $12.63 | $241K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 2,738 | $12.49 | $34K |
| Sale | Common Stock | 16,322 | $13.48 | $220K |
Holdings After Transaction:
Stock Option (right to buy) — 111,163 contracts (Direct);
Common Stock — 455,878 shares (Direct)
Footnotes (6)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.10 to $13.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F6. The option is fully vested and exercisable.
Key Figures
Options exercised: 44,166 shares
Shares sold: 57,180 shares
Option exercise price: $7.27 per share
+5 more
8 metrics
Options exercised
44,166 shares
Stock options converted to common stock at $7.27
Shares sold
57,180 shares
Open-market sales across four Form 4 sale entries
Option exercise price
<money>$7.27</money> per share
Exercise or conversion price for stock options
Sale price example
<money>$12.63</money> per share
One reported weighted-average sale price on March 30, 2026
Sale price example
<money>$13.45</money> per share
One reported weighted-average sale price on March 31, 2026
Post-transaction holding
455,878 shares
Common stock directly owned after final reported sale
Option expiration
<date>February 7, 2029</date>
Expiration date of exercised stock options
10b5-1 plan adoption date
<date>November 18, 2025</date>
Date the Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested and exercisable financial
"The option is fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein do in this Form 4?
Julie Rubinstein, President and COO of Adaptive Biotechnologies, exercised stock options and sold common shares. She converted options into 44,166 common shares, then sold 57,180 shares in open-market transactions, all under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.
What stock options did Julie Rubinstein exercise in Adaptive Biotechnologies (ADPT)?
She exercised fully vested stock options covering 44,166 shares of Adaptive Biotechnologies common stock. These options had an exercise price of $7.27 per share and an expiration date of February 7, 2029, and were described in the filing as fully vested and exercisable.
Was Julie Rubinstein’s trading in Adaptive Biotechnologies (ADPT) pre-planned?
Yes. The Form 4 states that all reported transactions were effected under a Rule 10b5-1 trading plan. That plan was adopted by Julie Rubinstein on November 18, 2025, indicating the sales were scheduled in advance rather than made on a discretionary basis.
What do the weighted-average price footnotes mean in this Adaptive Biotechnologies (ADPT) Form 4?
The footnotes explain that reported sale prices are weighted averages across multiple trades. Individual sales occurred within specified price ranges, and the reporting person commits to provide exact trade-by-trade prices and share amounts within each range upon request to investors or regulators.
AI-generated analysis. How Rhea-AI works. Not financial advice.
